Európska únia - čeština - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertenze - agens působící na systém renin-angiotenzin - léčba esenciální hypertenze.

Európska únia - čeština - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertenze - agens působící na systém renin-angiotenzin - léčba esenciální hypertenze.

Európska únia - čeština - EMA (European Medicines Agency)

orion corporation - levodopu, karbidopu, entakapon - parkinsonova choroba - antiparkinsonické léky - stalevo je indikován k léčbě dospělých pacientů s parkinsonovou chorobou a konec of-motorickými výkyvy nejsou stabilizovala na levodopu / dopadekarboxylázy (ddc)-léčba inhibitorem.

Európska únia - čeština - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastická činidla - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

merus labs luxco ii s.a r.l., luxembourg array - 800 isosorbid-dinitrÁt - tvrdá tobolka s prodlouženým uvolňováním - 120mg - isosorbid-dinitrÁt

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

merus labs luxco ii s.a r.l., luxembourg array - 800 isosorbid-dinitrÁt - tableta s prodlouženým uvolňováním - 20mg - isosorbid-dinitrÁt

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

merus labs luxco ii s.a r.l., luxembourg array - 800 isosorbid-dinitrÁt - tableta s prodlouženým uvolňováním - 40mg - isosorbid-dinitrÁt

Európska únia - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecyklin - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakteriální látky pro systémové použití, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek. vhodné použití antibakteriálních látek.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

neuraxpharm bohemia s.r.o., praha array - 936 methylfenidÁt-hydrochlorid; 936 methylfenidÁt-hydrochlorid - tableta s prodlouženým uvolňováním - 18mg - methylfenidÁt

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

neuraxpharm bohemia s.r.o., praha array - 936 methylfenidÁt-hydrochlorid; 936 methylfenidÁt-hydrochlorid - tableta s prodlouženým uvolňováním - 36mg - methylfenidÁt